Citizens Maintains Market Outperform on Iovance Biotherapeutics, Raises Price Target to $12
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsPrice Target
Citizens analyst Reni J. Benjamin maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Market Outperform and raises the price target from $8 to $12.
Citizens analyst Reni J. Benjamin maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Market Outperform and raises the price target from $8 to $12.